DK3954225T3 - Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe - Google Patents
Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe Download PDFInfo
- Publication number
- DK3954225T3 DK3954225T3 DK21173142.7T DK21173142T DK3954225T3 DK 3954225 T3 DK3954225 T3 DK 3954225T3 DK 21173142 T DK21173142 T DK 21173142T DK 3954225 T3 DK3954225 T3 DK 3954225T3
- Authority
- DK
- Denmark
- Prior art keywords
- capped
- synthesizing
- oligonucleotide primers
- initiating
- rna
- Prior art date
Links
- 239000003155 DNA primer Substances 0.000 title 1
- 230000000977 initiatory effect Effects 0.000 title 1
- 230000002194 synthesizing effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562221248P | 2015-09-21 | 2015-09-21 | |
| EP16849423.5A EP3352584B1 (en) | 2015-09-21 | 2016-09-20 | Compositions and methods for synthesizing 5'-capped rnas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3954225T3 true DK3954225T3 (da) | 2024-01-02 |
Family
ID=58387109
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21173278.9T DK3906789T3 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
| DK21173142.7T DK3954225T3 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
| DK16849423.5T DK3352584T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntese af 5'-rna¿er med kappe |
| DK22175377.5T DK4104687T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe |
| DK22190426.1T DK4140491T3 (da) | 2015-09-21 | 2016-09-20 | Fremgangsmåde til syntetisering af RNA'er med 5'-kappe |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21173278.9T DK3906789T3 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16849423.5T DK3352584T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntese af 5'-rna¿er med kappe |
| DK22175377.5T DK4104687T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe |
| DK22190426.1T DK4140491T3 (da) | 2015-09-21 | 2016-09-20 | Fremgangsmåde til syntetisering af RNA'er med 5'-kappe |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10913768B2 (da) |
| EP (7) | EP3954224A1 (da) |
| JP (3) | JP6814997B2 (da) |
| KR (2) | KR102500198B1 (da) |
| CN (5) | CN117025590A (da) |
| AU (4) | AU2016328645C1 (da) |
| CA (2) | CA3218662A1 (da) |
| CY (1) | CY1124306T1 (da) |
| DK (5) | DK3906789T3 (da) |
| ES (2) | ES2879686T3 (da) |
| FI (4) | FI4140491T3 (da) |
| HK (1) | HK1255236A1 (da) |
| HR (1) | HRP20211091T1 (da) |
| HU (2) | HUE055458T2 (da) |
| LT (5) | LT3906789T (da) |
| PL (2) | PL4140491T3 (da) |
| PT (5) | PT4140491T (da) |
| RS (1) | RS62129B1 (da) |
| SI (5) | SI4140491T1 (da) |
| WO (1) | WO2017053297A1 (da) |
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6814997B2 (ja) | 2015-09-21 | 2021-01-20 | トリリンク バイオテクノロジーズ エルエルシー | ５’キャップ付ｒｎａを合成するための組成物および方法 |
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| EP4163374A1 (en) | 2015-11-23 | 2023-04-12 | The Regents of the University of California | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 |
| EP3529255A1 (en) | 2016-10-19 | 2019-08-28 | Arcturus Therapeutics, Inc. | Trinucleotide mrna cap analogs |
| JP2020508056A (ja) | 2017-02-22 | 2020-03-19 | クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ | 遺伝子編集のための組成物および方法 |
| SG10202110491PA (en) | 2017-03-24 | 2021-11-29 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| PE20191842A1 (es) | 2017-05-08 | 2019-12-31 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus |
| EP3622062A4 (en) | 2017-05-10 | 2020-10-14 | The Regents of the University of California | DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9 |
| JP2020530980A (ja) | 2017-07-04 | 2020-11-05 | キュアバック アーゲー | 新規核酸分子 |
| EP3668971B1 (en) * | 2017-08-18 | 2024-04-10 | ModernaTX, Inc. | Rna polymerase variants |
| US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
| BR112020005323A2 (pt) | 2017-09-29 | 2020-09-24 | Intellia Therapeutics, Inc. | polinucleotídeos, composições e métodos para edição de genoma |
| TW201932479A (zh) | 2017-09-29 | 2019-08-16 | 美商英特利亞醫療公司 | 用於ttr基因編輯及治療attr澱粉樣變性之組合物及方法 |
| CA3093509A1 (en) * | 2018-03-15 | 2019-09-19 | Biontech Rna Pharmaceuticals Gmbh | 5'-cap-tri nucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy |
| US20210361761A1 (en) | 2018-04-05 | 2021-11-25 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| CN112292395A (zh) | 2018-04-17 | 2021-01-29 | 库瑞瓦格股份公司 | 用于疫苗接种的新型rsv rna分子和组合物 |
| EP3813874A1 (en) | 2018-06-27 | 2021-05-05 | CureVac AG | Novel lassa virus rna molecules and compositions for vaccination |
| JP7352581B2 (ja) | 2018-06-28 | 2023-09-28 | キュアバック アールエヌエイ プリンター ゲーエムベーハー | Ｒｎａインビトロ転写用バイオリアクター |
| JP7445657B2 (ja) | 2018-12-06 | 2024-03-07 | アークトゥラス・セラピューティクス・インコーポレイテッド | オルニチントランスカルバミラーゼ欠損症を処置するための組成物および方法 |
| CN113453707A (zh) | 2018-12-21 | 2021-09-28 | 库瑞瓦格股份公司 | 用于疟疾疫苗的rna |
| SG11202106666UA (en) | 2018-12-21 | 2021-07-29 | Curevac Ag | Methods for rna analysis |
| WO2020161342A1 (en) | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| US20220162586A1 (en) | 2019-02-11 | 2022-05-26 | Ethris Gmbh | Mrna purification by tangential flow filtration |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| JP2022525428A (ja) | 2019-03-28 | 2022-05-13 | インテリア セラピューティクス，インコーポレイテッド | Ｔｔｒガイドｒｎａと、ｒｎａガイドｄｎａ結合剤をコードするポリヌクレオチドとを含む組成物および方法 |
| CA3135172A1 (en) | 2019-03-28 | 2020-10-01 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for polypeptide expression |
| WO2020198706A1 (en) | 2019-03-28 | 2020-10-01 | Intellia Therapeutics, Inc. | Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof |
| WO2020214806A1 (en) * | 2019-04-16 | 2020-10-22 | The Regents Of The University Of California | Protein translational control |
| BR112021023656A2 (pt) * | 2019-05-24 | 2022-02-01 | Ultragenyx Pharmaceutical Inc | Composições e métodos para tratamento de hemocromatose |
| AU2020282369A1 (en) | 2019-05-30 | 2022-01-20 | Gritstone Bio, Inc. | Modified adenoviruses |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| EP4003508A1 (en) | 2019-07-31 | 2022-06-01 | Memorial Sloan Kettering Cancer Center | Perfusion modulated tumor dose sculpting with single dose radiotherapy |
| WO2021028439A1 (en) | 2019-08-14 | 2021-02-18 | Curevac Ag | Rna combinations and compositions with decreased immunostimulatory properties |
| BR112022011803A2 (pt) | 2019-12-20 | 2022-08-30 | Curevac Ag | Nanopartículas de lipídio para entrega de ácidos nucleicos |
| IL293571A (en) | 2020-02-04 | 2022-08-01 | Curevac Ag | Corona virus vaccine |
| US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
| PL432884A1 (pl) * | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| PL432883A1 (pl) * | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| WO2021172204A1 (ja) * | 2020-02-28 | 2021-09-02 | 国立研究開発法人科学技術振興機構 | キャップ化ｒｎａの製造方法 |
| CN113151312B (zh) * | 2020-03-02 | 2022-12-09 | 中国科学院微生物研究所 | 新型冠状病毒SARS-CoV-2 mRNA疫苗及其制备方法和应用 |
| AU2021236068A1 (en) | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| WO2021198157A1 (en) | 2020-03-30 | 2021-10-07 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| WO2021216776A2 (en) * | 2020-04-21 | 2021-10-28 | Gritstone Bio, Inc. | Capping compounds, compositions and methods of use thereof |
| WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
| AU2021279312A1 (en) | 2020-05-29 | 2022-12-15 | CureVac SE | Nucleic acid based combination vaccines |
| US20220002716A1 (en) * | 2020-07-02 | 2022-01-06 | Life Technologies Corporation | Trinucleotide cap analogs, preparation and uses thereof |
| EP4172194A1 (en) | 2020-07-31 | 2023-05-03 | CureVac SE | Nucleic acid encoded antibody mixtures |
| EP4192496A2 (en) | 2020-08-06 | 2023-06-14 | Gritstone bio, Inc. | Multiepitope vaccine cassettes |
| CN113278668A (zh) * | 2020-08-20 | 2021-08-20 | 深圳市瑞吉生物科技有限公司 | 一种Cap2结构5′帽子类似物及其制备方法和应用 |
| US20240066114A1 (en) | 2020-08-31 | 2024-02-29 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
| WO2022049093A1 (en) | 2020-09-01 | 2022-03-10 | CureVac RNA Printer GmbH | Manufacturing device for a pharmaceutical product |
| EP4208549A1 (en) * | 2020-09-04 | 2023-07-12 | Verve Therapeutics, Inc. | Compositions and methods for capping rnas |
| EP4234567A1 (en) | 2020-10-20 | 2023-08-30 | ST Pharm Co., Ltd. | Oligonucleotide for 5'-capped rna synthesis |
| CA3193238A1 (en) | 2020-11-27 | 2022-06-02 | Benyamin YAZDAN PANAH | A device for preparing a dna product by means of capillary polymerase chain reaction |
| EP4259161A1 (en) | 2020-12-09 | 2023-10-18 | BioNTech SE | Rna manufacturing |
| CA3205000A1 (en) | 2020-12-11 | 2022-06-16 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing involving deamination |
| WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
| WO2022135993A2 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| EP4267178A1 (en) | 2020-12-22 | 2023-11-01 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| JP2024501022A (ja) | 2020-12-28 | 2024-01-10 | アークトゥルス セラピューティクス， インコーポレイテッド | Ｈｂｖを標的とする転写活性化因子様エフェクターヌクレアーゼ（ｔａｌｅｎ） |
| US20240102065A1 (en) | 2021-01-27 | 2024-03-28 | CureVac SE | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| JP2024506557A (ja) | 2021-01-29 | 2024-02-14 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用 |
| US20240122865A1 (en) | 2021-02-19 | 2024-04-18 | Pfizer Inc. | Methods of Protecting RNA |
| CN117377491A (zh) | 2021-03-26 | 2024-01-09 | 葛兰素史克生物有限公司 | 免疫原性组合物 |
| EP4312988A2 (en) | 2021-03-31 | 2024-02-07 | CureVac SE | Syringes containing pharmaceutical compositions comprising rna |
| KR20220140140A (ko) | 2021-04-09 | 2022-10-18 | 한미정밀화학주식회사 | 캡핑된 올리고뉴클레오티드 프라이머 및 이의 용도 |
| CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
| WO2022235853A1 (en) | 2021-05-04 | 2022-11-10 | BioNTech SE | Immunogen selection |
| KR20240038705A (ko) | 2021-06-22 | 2024-03-25 | 인텔리아 테라퓨틱스, 인크. | 간 유전자의 생체 내 편집 방법 |
| JPWO2023282245A1 (da) | 2021-07-05 | 2023-01-12 | ||
| EP4116313A1 (en) | 2021-07-07 | 2023-01-11 | Westfälische Wilhelms-Universität Münster | Cap analog for the 5'-end of eukaryotic messenger rnas |
| KR20240042414A (ko) | 2021-07-29 | 2024-04-02 | 비온테크 에스이 | 흑색종의 치료용 조성물 및 방법 |
| CA3171750A1 (en) | 2021-07-30 | 2023-02-02 | Tim SONNTAG | Mrnas for treatment or prophylaxis of liver diseases |
| WO2023007019A1 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
| CA3230030A1 (en) | 2021-08-31 | 2023-03-09 | Bo Sung Choi | Mrna cap analogue and use thereof |
| WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
| CA3230031A1 (en) | 2021-09-03 | 2023-03-09 | Patrick Baumhof | Novel lipid nanoparticles for delivery of nucleic acids |
| CN113957108A (zh) * | 2021-09-09 | 2022-01-21 | 上海兆维科技发展有限公司 | 一种加帽rna的合成方法以及加帽rna转录反应液 |
| EP4169534A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide complexes and uses |
| WO2023067126A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
| WO2023067124A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4285933A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| WO2023067123A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169578A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4169580A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4286003A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4286394A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4186528A1 (en) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharide complexes and uses |
| WO2023067125A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
| WO2023067121A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4285932A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4286004A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4169579A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| TW202325848A (zh) | 2021-11-03 | 2023-07-01 | 美商英特利亞醫療公司 | 用於基因體編輯之多核苷酸、組合物及方法 |
| KR20230083197A (ko) | 2021-12-01 | 2023-06-09 | 에스티팜 주식회사 | 5'-캡핑된 rna 합성용 올리고뉴클레오티드 |
| WO2023115495A1 (zh) * | 2021-12-23 | 2023-06-29 | 北京毅新博创生物科技有限公司 | 质谱法检测mRNA加帽效率的方法 |
| WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| KR20230123318A (ko) | 2022-02-16 | 2023-08-23 | 에스티팜 주식회사 | 5'-캡핑된 rna 합성용 올리고뉴클레오티드 |
| GB2615784A (en) | 2022-02-18 | 2023-08-23 | Phion Therapeutics Ltd | mRNA vaccine |
| CN115260264B (zh) * | 2022-02-28 | 2023-06-09 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的化合物及其应用 |
| WO2023167880A2 (en) * | 2022-03-01 | 2023-09-07 | Verve Therapeutics, Inc. | Compositions and methods for capping rnas |
| WO2023166425A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
| TW202403046A (zh) | 2022-03-21 | 2024-01-16 | 瑞士商Ｃｒｉｓｐｒ治療公司 | 用於治療脂蛋白相關的疾病之方法及組成物 |
| WO2023191342A1 (ko) | 2022-03-31 | 2023-10-05 | 한미정밀화학 주식회사 | mRNA 캡 유사체 및 이의 용도 |
| CN114685588B (zh) * | 2022-05-05 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含开环核苷结构的起始加帽寡核苷酸引物 |
| GB2618818A (en) | 2022-05-18 | 2023-11-22 | Phion Therapeutics Ltd | Vaccine |
| WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2023232747A1 (en) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
| WO2023235362A1 (en) * | 2022-05-31 | 2023-12-07 | Nutcracker Therapeutics, Inc. | Rna cap analogs and methods of use |
| WO2023245113A1 (en) | 2022-06-16 | 2023-12-21 | Intellia Therapeutics, Inc. | Methods and compositions for genetically modifying a cell |
| CN115057903B (zh) * | 2022-06-22 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含吗啉环结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| CN115109110A (zh) * | 2022-06-22 | 2022-09-27 | 江苏申基生物科技有限公司 | 一种含六元糖环结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| WO2023246860A1 (zh) * | 2022-06-22 | 2023-12-28 | 江苏申基生物科技有限公司 | 一种起始加帽寡核苷酸引物及其制备方法和应用 |
| CN114853836A (zh) * | 2022-06-24 | 2022-08-05 | 江苏申基生物科技有限公司 | 一种含gna结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN114941018B (zh) * | 2022-06-28 | 2023-09-22 | 翌圣生物科技(上海)股份有限公司 | cap1帽类似物的合成方法 |
| KR20240010238A (ko) | 2022-07-15 | 2024-01-23 | 한미정밀화학주식회사 | 캡 유사체 및 이의 용도 |
| US11898186B1 (en) | 2022-08-10 | 2024-02-13 | Genscript Usa Inc. | Compositions and methods for preparing capped mRNA |
| CN115925773A (zh) * | 2022-08-23 | 2023-04-07 | 合肥华纳生物医药科技有限公司 | 一种新型信使核糖核酸帽类似物 |
| WO2024044741A2 (en) * | 2022-08-26 | 2024-02-29 | Trilink Biotechnologies, Llc | Efficient method for making highly purified 5'-capped oligonucleotides |
| CN117645642A (zh) * | 2022-09-05 | 2024-03-05 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的化合物及其应用 |
| WO2024055018A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| WO2024055017A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024068674A1 (en) | 2022-09-26 | 2024-04-04 | BioNTech SE | Nucleic acid complexes and uses thereof |
| WO2024075022A2 (en) | 2022-10-04 | 2024-04-11 | BioNTech SE | Rna constructs and uses thereof |
| WO2024074634A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1997A (en) | 1841-03-03 | Improvement in the mode of rendering fabrics water-proof | ||
| EP0081099A3 (en) * | 1981-12-04 | 1983-08-10 | Sloan-Kettering Institute For Cancer Research | Capped oligonucleotide anti-viral agents |
| DE3148702C2 (de) * | 1981-12-09 | 1985-05-15 | Dieter Gräßlin Feinwerktechnik, 7742 St Georgen | Programmierbare Steuereinrichtung, insbesondere für schaltende Zeitmeßgeräte |
| US5837852A (en) | 1993-10-14 | 1998-11-17 | Bristol-Myers Squibb Company | Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease |
| US6965041B1 (en) | 1999-03-24 | 2005-11-15 | The United States Of America As Represented By The Department Of Health And Human Services | N-acylphosphoramidites and their use in oligonucleotide synthesis |
| US7074596B2 (en) * | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| CA2589406A1 (en) | 2004-12-09 | 2006-06-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas |
| CA2653841C (en) | 2006-06-01 | 2016-07-19 | Trilink Biotechnologies | Chemically modified oligonucleotide primers for nucleic acid amplification |
| WO2008016473A2 (en) * | 2006-07-28 | 2008-02-07 | Applera Corporation | Dinucleotide mrna cap analogs |
| US20080248469A1 (en) | 2006-08-16 | 2008-10-09 | Applera Corporation | Methods for Identifying Nucleotides of Interest in Target Polynucleotides |
| PT2167523E (pt) | 2007-06-19 | 2014-09-22 | Univ Louisiana State | Síntese e utilização de análogos fosforotiolato antireversos do capuz de arn mensageiro |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| WO2011157617A1 (en) | 2010-06-17 | 2011-12-22 | Febit Holding Gmbh | Complex set of mirna libraries |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| EP2971098B1 (en) | 2013-03-14 | 2018-11-21 | Translate Bio, Inc. | Quantitative assessment for cap efficiency of messenger rna |
| JP6148592B2 (ja) | 2013-10-15 | 2017-06-14 | ヤマハ発動機株式会社 | 車速決定システム、安定制御システム及びそれを備えた鞍乗り型車両 |
| CN107223128A (zh) | 2014-12-16 | 2017-09-29 | 诺华股份有限公司 | 末端加帽的核酸分子 |
| JP6814997B2 (ja) * | 2015-09-21 | 2021-01-20 | トリリンク バイオテクノロジーズ エルエルシー | ５’キャップ付ｒｎａを合成するための組成物および方法 |
| WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
| EP3529255A1 (en) | 2016-10-19 | 2019-08-28 | Arcturus Therapeutics, Inc. | Trinucleotide mrna cap analogs |
| CA3093509A1 (en) | 2018-03-15 | 2019-09-19 | Biontech Rna Pharmaceuticals Gmbh | 5'-cap-tri nucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy |
| US11072808B2 (en) | 2018-10-04 | 2021-07-27 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed RNA |
| PL432883A1 (pl) | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| PL432884A1 (pl) | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| WO2021213924A1 (en) | 2020-04-22 | 2021-10-28 | BioNTech SE | Coronavirus vaccine |
| US20220002716A1 (en) | 2020-07-02 | 2022-01-06 | Life Technologies Corporation | Trinucleotide cap analogs, preparation and uses thereof |
| EP4234567A1 (en) | 2020-10-20 | 2023-08-30 | ST Pharm Co., Ltd. | Oligonucleotide for 5'-capped rna synthesis |
-
2016
- 2016-09-20 JP JP2018515136A patent/JP6814997B2/ja active Active
- 2016-09-20 CN CN202311200887.4A patent/CN117025590A/zh active Pending
- 2016-09-20 KR KR1020187010893A patent/KR102500198B1/ko active IP Right Grant
- 2016-09-20 PT PT221904261T patent/PT4140491T/pt unknown
- 2016-09-20 FI FIEP22190426.1T patent/FI4140491T3/fi active
- 2016-09-20 ES ES16849423T patent/ES2879686T3/es active Active
- 2016-09-20 SI SI201631757T patent/SI4140491T1/sl unknown
- 2016-09-20 CA CA3218662A patent/CA3218662A1/en active Pending
- 2016-09-20 CN CN202110537080.4A patent/CN113584020A/zh active Pending
- 2016-09-20 CN CN202211046591.7A patent/CN116590285A/zh active Pending
- 2016-09-20 LT LTEP21173278.9T patent/LT3906789T/lt unknown
- 2016-09-20 CN CN201680067458.6A patent/CN108366604A/zh active Pending
- 2016-09-20 PT PT168494235T patent/PT3352584T/pt unknown
- 2016-09-20 PT PT211731427T patent/PT3954225T/pt unknown
- 2016-09-20 EP EP21173131.0A patent/EP3954224A1/en active Pending
- 2016-09-20 SI SI201631772T patent/SI3906789T1/sl unknown
- 2016-09-20 AU AU2016328645A patent/AU2016328645C1/en active Active
- 2016-09-20 SI SI201631802T patent/SI4104687T1/sl unknown
- 2016-09-20 PT PT211732789T patent/PT3906789T/pt unknown
- 2016-09-20 DK DK21173278.9T patent/DK3906789T3/da active
- 2016-09-20 LT LTEP22190426.1T patent/LT4140491T/lt unknown
- 2016-09-20 DK DK21173142.7T patent/DK3954225T3/da active
- 2016-09-20 EP EP22175377.5A patent/EP4104687B1/en active Active
- 2016-09-20 SI SI201631773T patent/SI3954225T1/sl unknown
- 2016-09-20 CN CN202310734863.0A patent/CN116751827B/zh active Active
- 2016-09-20 DK DK16849423.5T patent/DK3352584T3/da active
- 2016-09-20 PT PT221753775T patent/PT4104687T/pt unknown
- 2016-09-20 FI FIEP22175377.5T patent/FI4104687T3/fi active
- 2016-09-20 CA CA2999274A patent/CA2999274C/en active Active
- 2016-09-20 EP EP23192203.0A patent/EP4276189A3/en active Pending
- 2016-09-20 FI FIEP21173278.9T patent/FI3906789T3/fi active
- 2016-09-20 EP EP21173142.7A patent/EP3954225B1/en active Active
- 2016-09-20 DK DK22175377.5T patent/DK4104687T3/da active
- 2016-09-20 LT LTEP22175377.5T patent/LT4104687T/lt unknown
- 2016-09-20 RS RS20210857A patent/RS62129B1/sr unknown
- 2016-09-20 SI SI201631248T patent/SI3352584T1/sl unknown
- 2016-09-20 EP EP16849423.5A patent/EP3352584B1/en active Active
- 2016-09-20 ES ES22190426T patent/ES2964690T3/es active Active
- 2016-09-20 PL PL22190426.1T patent/PL4140491T3/pl unknown
- 2016-09-20 KR KR1020237004950A patent/KR20230026535A/ko active IP Right Grant
- 2016-09-20 HU HUE16849423A patent/HUE055458T2/hu unknown
- 2016-09-20 WO PCT/US2016/052670 patent/WO2017053297A1/en active Application Filing
- 2016-09-20 HU HUE22190426A patent/HUE064227T2/hu unknown
- 2016-09-20 FI FIEP21173142.7T patent/FI3954225T3/fi active
- 2016-09-20 EP EP22190426.1A patent/EP4140491B1/en active Active
- 2016-09-20 LT LTEP21173142.7T patent/LT3954225T/lt unknown
- 2016-09-20 EP EP21173278.9A patent/EP3906789B1/en active Active
- 2016-09-20 LT LTEP16849423.5T patent/LT3352584T/lt unknown
- 2016-09-20 PL PL16849423T patent/PL3352584T3/pl unknown
- 2016-09-20 DK DK22190426.1T patent/DK4140491T3/da active
- 2016-09-20 US US15/761,957 patent/US10913768B2/en active Active
-
2018
- 2018-11-09 HK HK18114366.7A patent/HK1255236A1/zh unknown
- 2018-12-26 US US16/232,435 patent/US10519189B2/en active Active
-
2019
- 2019-04-01 US US16/371,317 patent/US10494399B2/en active Active
-
2020
- 2020-11-06 US US17/091,422 patent/US11878991B2/en active Active
- 2020-12-10 JP JP2020204713A patent/JP7082174B2/ja active Active
-
2021
- 2021-07-07 CY CY20211100612T patent/CY1124306T1/el unknown
- 2021-07-08 HR HRP20211091TT patent/HRP20211091T1/hr unknown
- 2021-07-19 AU AU2021206780A patent/AU2021206780C1/en active Active
- 2021-08-02 US US17/392,170 patent/US11414453B2/en active Active
-
2022
- 2022-04-22 JP JP2022070512A patent/JP2022109973A/ja active Pending
- 2022-05-26 US US17/804,192 patent/US11578095B2/en active Active
-
2023
- 2023-03-29 AU AU2023201915A patent/AU2023201915A1/en active Pending
- 2023-09-13 AU AU2023229522A patent/AU2023229522A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3954225T3 (da) | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe | |
| ZA201905396B (en) | Trans-replicating rna | |
| DK3445850T3 (da) | Fremgangsmåder til tilvejebringelse af enkeltstrenget rna | |
| EP3668971A4 (en) | RNA POLYMERASE VARIANTS | |
| DK3337902T3 (da) | 3'-utr-sekvenser til stabilisering af rna | |
| IL288461A (en) | Targeted nucleic acid conjugate preparations | |
| DK3319622T3 (da) | Fremgangsmåde til fremstilling af rna-molekylesammensætninger | |
| DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
| PL3271421T3 (pl) | Utwardzalne kompozycje silikonowe | |
| DK3609529T3 (da) | Rna til behandling af autoimmune sygdomme | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3512863T3 (da) | 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus | |
| DK3350266T3 (da) | Strålingshærdelige sammensætninger til coatings med lav glans | |
| IL271553A (en) | Variants of t7 RNA polymerase | |
| DK3536324T3 (da) | 4-oxo-3,4-dihydro-1,2,3-benzotriaziner som modulatorer af gpr139 | |
| IL271547A (en) | T7 rna polymerase variants | |
| SG11201808538QA (en) | Trans-splicing rna (tsrna) | |
| ZA201701132B (en) | Novel 2,5-substituted pyrimidines as pde inhibitors | |
| DK3662925T3 (da) | Sammensætning, der omfatter fsh, til behandling af infertilitet | |
| HK1247229A1 (zh) | 溶劑型底漆組合物 | |
| DK3525807T3 (da) | Hæmmer af rna-polymerase ii | |
| DK3325621T3 (da) | Kloning af en-strenget nucleinsyre | |
| DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner | |
| DK3184506T3 (da) | Kationisk lipid til levering af nukleinsyre. | |
| DK3515454T3 (da) | Krystallinsk polymorf form af 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinan |